What's the latest on sulphonylureas in the management of type 2 diabetes?

South African Family Practice

Volumn 55, Issue 6, 2013, Pages 501-503

  Mkele, Gail ^a  

^a NONE

Author keywords

Chlorpropamide; Glibenclamide; Gliclazide; Glimepiride; Glipizide; Sulphonylureas; Type 2 diabetes

Indexed keywords

CHLORPROPAMIDE; DIAMICRON MR; EXENDIN 4; GLIBENCLAMIDE; GLIBENCLAMIDE PLUS METFORMIN; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1; INCRETIN; LIRAGLUTIDE; METFORMIN; SAXAGLIPTIN; SULFONYLUREA; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ARTICLE; BODY WEIGHT DISORDER; CELL FUNCTION; CELL VIABILITY; DRUG POTENCY; DRUG SAFETY; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL;

EID: 84892382797     PISSN: 20786190     EISSN: 20786204     Source Type: Journal    
DOI: 10.1080/20786204.2013.10874405     Document Type: Article

References (14)

1. Amod A, Ascott-Evans BH, Berg GI, et al. The 2012 SEMDSA guideline for the management of type 2 diabetes (revised). Glucose control non-insulin therapies. JEMDSA. 2012;17(2 Suppl 1):S23-S31.
2. Amod A, Ascott-Evans BH, Berg GI, et al. The 2012 SEMDSA guideline for the management of type 2 diabetes (revised). The 2012 SEMDSA treatment algorithm for type 2 diabetes. JEMDSA. 2012;17(2 Suppl 1):S36-S40.
3. thed. In: Rossiter D, editor. Rondebosch: Health and Medical Publishing Group, Cape Media House; 2012.
4. Fowler MJ. Diabetes treatment: oral agents. Clinical Diabetes. July 2010;28(3):132-136.
5. Melander A, Lebovits HE, Faber OK. Sulfonylureas. Why, which and how? Diabetes Care. 1990;13(Suppl 3):18-25.
6. Hanefeld M. Pioglitazone and sulfonylureas: effectively treating type 2 diabetes. Int J Clin Pract. 2007;61 Suppl 153:20-27.
7. Donovan PJ, McIntyre HD. Drugs for gestational diabetes. Aust Prescr. 2010;33:141-144.
8. Package insert, Daonil®. Aventis; 1989.
9. Rotenstein LS, Kozak BM, Shivers JP, et al. The ideal diabetes therapy: what will it look like? How close are we? Clinical Diabetes. 2012;30(2):44-53.
10. Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medication for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2011;154(9):602-613.
11. Caulfield MT, O'Brien KD. Cardiovascular safety of oral antidiabetic agents: the insulin secretagogues. Clinical Diabetes. 2002;20(2):81-84.
12. Evans JMM, Ogston SA, Emslie-Smith A, et al. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia. 2006;49(5): 930-936.
13. Mintz ML. Sulfonylureas in diabetes: why so controversial? Medscape [homepage on the Internet]. 2012. Available from: http://www.medscape.com/ viewarticle/761098_print
14. Standard treatment guidelines and essential medicines list, hospital level adults. Essential Drug Programme. Pretoria: The National Department of Health; 2012.